Jeff Aronin's Emalex raises $35M Series C; British protein degradation biotech emerges from stealth
Jeff Aronin has a new raise in place for one of his portfolio companies.
Emalex Biosciences is banking a $35 million C round for its work on a drug for Tourette syndrome and stuttering. The biotech will use the money to advance its clinical work, with 3 Phase II studies underway for ecopipam (EBS-101).
Aronin is perhaps best known for Marathon, a controversial play that took a cheap, generic steroid through the FDA and priced it at $89,000 a year after an approval. He disbanded the company and sold the steroid to PTC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
